SAGA Diagnostics is a perzonalised cancer diagnostics and disease monitoring company founded in Lund, 2016. With the mission to intercept cancer at the earliest stages when it’s most treatable. SAGA is focused on ultra-sensitive detection of Molecular Residual Disease (MRD) empowering treatment decisions with greater insight and confidence.
Its flagship test, Pathlight™, is a personalised, blood-based MRD assay built on patient-specific structural variants, enabling best-in-class sensitivity, specificity, and shorter lead times. Commercially available in the U.S. across multiple cancer types and supports both clinical care and drug development.
